Year: 2023

DS_logo_portrait_format_4color_rgb_120206

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

First phase 3 results for Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC demonstrated statistically significant improvement in progression-free survival versus...

HADLIMA_adalimumab-bwwd_PushTouch_Autoinjector_Close-up

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMAâ„¢ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including...